Targeting CREB in Cancer Therapy: A Key Candidate or One of Many? An Update.
CREB
GSKJ4
cancer therapy
drug inhibitors
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Oct 2020
28 Oct 2020
Historique:
received:
02
10
2020
revised:
23
10
2020
accepted:
27
10
2020
entrez:
31
10
2020
pubmed:
1
11
2020
medline:
1
11
2020
Statut:
epublish
Résumé
Intratumor heterogeneity (ITH) is considered the major disorienting factor in cancer treatment. As a result of stochastic genetic and epigenetic alterations, the appearance of a branched evolutionary shape confers tumor plasticity, causing relapse and unfavorable clinical prognosis. The growing evidence in cancer discovery presents to us "the great paradox" consisting of countless potential targets constantly discovered and a small number of candidates being effective in human patients. Among these, cyclic-AMP response element-binding protein (CREB) has been proposed as proto-oncogene supporting tumor initiation, progression and metastasis. Overexpression and hyperactivation of CREB are frequently observed in cancer, whereas genetic and pharmacological CREB downregulation affects proliferation and apoptosis. Notably, the present review is designed to investigate the feasibility of targeting CREB in cancer therapy. In particular, starting with the latest CREB evidence in cancer pathophysiology, we evaluate the advancement state of CREB inhibitor design, including the histone lysine demethylases JMJD3/UTX inhibitor GSKJ4 that we newly identified as a promising CREB modulator in leukemia cells. Moreover, an accurate analysis of strengths and weaknesses is also conducted to figure out whether CREB can actually represent a therapeutic candidate or just one of the innumerable preclinical cancer targets.
Identifiants
pubmed: 33126560
pii: cancers12113166
doi: 10.3390/cancers12113166
pmc: PMC7693618
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Clin Oncol. 2010 Jun 20;28(18):2947-51
pubmed: 20458043
Mol Cell Biochem. 2013 Jul;379(1-2):51-8
pubmed: 23543137
Int J Mol Sci. 2018 Jan 30;19(2):
pubmed: 29385729
Mol Cancer Res. 2013 Nov;11(11):1462-77
pubmed: 24025972
Arch Biochem Biophys. 2014 Dec 1;563:79-93
pubmed: 24997364
Nature. 1987 Jul 9-15;328(6126):175-8
pubmed: 2885756
Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):449-55
pubmed: 16293792
Front Oncol. 2020 Jun 05;10:799
pubmed: 32582541
J Med Chem. 2012 Apr 26;55(8):4020-4
pubmed: 22458559
Life Sci. 2020 Sep 15;257:118020
pubmed: 32603820
Cell Mol Life Sci. 2020 Oct;77(20):4049-4067
pubmed: 32347317
Front Endocrinol (Lausanne). 2019 Nov 12;10:777
pubmed: 31781044
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Mol Cancer Ther. 2015 Jun;14(6):1276-85
pubmed: 25740244
Oncotarget. 2015 Jun 20;6(17):14970-81
pubmed: 26008971
Cancer Discov. 2015 Aug;5(8):806-20
pubmed: 26193902
FASEB J. 2019 Nov;33(11):11973-11992
pubmed: 31398290
Oncotarget. 2017 Jul 8;8(37):62131-62142
pubmed: 28977932
Medchemcomm. 2018 Jul 11;9(8):1249-1272
pubmed: 30151079
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
Front Oncol. 2016 Mar 29;6:69
pubmed: 27066453
Cancers (Basel). 2019 May 13;11(5):
pubmed: 31086012
Nat Cell Biol. 2016 Mar;18(3):246-54
pubmed: 26911908
J Cancer Res Clin Oncol. 2018 Jun;144(6):1065-1077
pubmed: 29594337
Arch Oral Biol. 2020 May;113:104712
pubmed: 32234582
Cancer Cell. 2005 Apr;7(4):351-62
pubmed: 15837624
Oncotarget. 2017 Aug 2;8(40):68591-68598
pubmed: 28978140
J Neurosci. 2014 Jul 16;34(29):9574-89
pubmed: 25031400
Cell Rep. 2018 May 8;23(6):1651-1664
pubmed: 29742423
Theranostics. 2018 Feb 16;8(7):2031-2043
pubmed: 29556371
Cell Mol Life Sci. 2018 Jan;75(2):209-223
pubmed: 28717873
Phytother Res. 2017 Jul;31(7):1078-1089
pubmed: 28544385
Nature. 2014 Oct 23;514(7523):513-7
pubmed: 25132549
Endocrine. 2005 Jun;27(1):17-24
pubmed: 16077166
Cancer Cell. 2015 Oct 12;28(4):515-528
pubmed: 26439496
Trends Cancer. 2015 Dec;1(4):231-241
pubmed: 28741514
Mol Carcinog. 2017 Sep;56(9):2022-2034
pubmed: 28383763
Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13078-83
pubmed: 11687654
Mol Pharmacol. 2012 Nov;82(5):814-23
pubmed: 22851716
Biomed Pharmacother. 2017 Mar;87:274-279
pubmed: 28063408
J Natl Cancer Inst. 2015 Jun 18;107(9):
pubmed: 26089541
Learn Mem. 2015 Jan 15;22(2):109-15
pubmed: 25593297
Mol Cell Endocrinol. 2002 Feb 22;187(1-2):115-24
pubmed: 11988318
Mol Cell Biochem. 2015 May;403(1-2):33-41
pubmed: 25648114
Ann Diagn Pathol. 2015 Oct;19(5):330-4
pubmed: 26245996
J Virol. 2005 May;79(10):6122-33
pubmed: 15857997
Neuropharmacology. 2014 Jun;81:256-66
pubmed: 24565641
Sci Transl Med. 2019 Sep 11;11(509):
pubmed: 31511426
Oncol Rep. 2017 Jun;37(6):3361-3368
pubmed: 28498439
J Hepatol. 2016 May;64(5):1090-1098
pubmed: 26809111
Cell Rep. 2019 Feb 5;26(6):1518-1532.e9
pubmed: 30726735
Transplant Proc. 2016 Jul-Aug;48(6):2221-34
pubmed: 27569974
Int J Oncol. 2019 May;54(5):1591-1600
pubmed: 30816492
N Engl J Med. 2020 Apr 9;382(15):1430-1442
pubmed: 32187457
Front Mol Neurosci. 2018 Aug 30;11:255
pubmed: 30214393
Cancers (Basel). 2019 May 28;11(6):
pubmed: 31141894
J Biol Chem. 2005 Apr 15;280(15):15103-10
pubmed: 15703171
Acta Pharm. 2018 Dec 1;68(4):497-506
pubmed: 31259702
Cell Mol Life Sci. 2013 Nov;70(21):3989-4008
pubmed: 23307074
Elife. 2020 Jan 28;9:
pubmed: 31990272
PLoS One. 2015 Apr 21;10(4):e0122628
pubmed: 25897662
Br J Cancer. 2019 Jul;121(2):101-108
pubmed: 31231121
Oncogene. 2014 Aug 28;33(35):4385-95
pubmed: 24096476
Cell Signal. 2015 Jul;27(7):1369-79
pubmed: 25843777
Cancer Res. 2018 Nov 1;78(21):6146-6158
pubmed: 30232221
Oncotarget. 2017 Oct 27;8(57):97439-97463
pubmed: 29228623
Int J Mol Sci. 2020 Jan 13;21(2):
pubmed: 31940975
Front Pharmacol. 2019 Oct 22;10:1245
pubmed: 31695614
Nat Commun. 2016 Mar 24;7:11081
pubmed: 27010597
Cancer Cell. 2016 Apr 11;29(4):440-451
pubmed: 27070699
Haematologica. 2013 Apr;98(4):602-10
pubmed: 23100280
Oncoscience. 2020 Mar 20;7(1-2):14-16
pubmed: 32258244
Oncotarget. 2016 Jun 7;7(23):35454-65
pubmed: 26934558
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
Int J Mol Sci. 2019 Apr 27;20(9):
pubmed: 31035588
PLoS One. 2016 Jan 06;11(1):e0146311
pubmed: 26735495
J Biol Chem. 2009 Sep 18;284(38):26194-206
pubmed: 19632997
Anal Biochem. 2005 May 15;340(2):259-71
pubmed: 15840499
Acta Neuropathol Commun. 2018 Jan 4;6(1):4
pubmed: 29301568
Hum Pathol. 2015 Feb;46(2):231-8
pubmed: 25476123
Oncotarget. 2015 Apr 30;6(12):10646-57
pubmed: 25825983
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
World J Mens Health. 2015 Apr;33(1):20-9
pubmed: 25927059
ACS Med Chem Lett. 2014 Aug 22;5(10):1104-9
pubmed: 25313320
Anticancer Res. 2016 Nov;36(11):6083-6092
pubmed: 27793936
Cancer Prev Res (Phila). 2008 Oct;1(5):316-28
pubmed: 19138976
Leukemia. 2016 Sep;30(9):1887-96
pubmed: 27118402
Liver Cancer. 2015 Dec;4(4):263-73
pubmed: 26734580
PLoS One. 2011;6(5):e19120
pubmed: 21625623
Cancers (Basel). 2017 May 30;9(6):
pubmed: 28556811
Bioessays. 2012 Apr;34(4):293-300
pubmed: 22331586
J Mol Biomark Diagn. 2017 Sep;8(5):
pubmed: 29285415
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
J Neurooncol. 2016 Sep;129(2):211-20
pubmed: 27294355
Bioorg Med Chem Lett. 2020 Oct 1;30(19):127455
pubmed: 32730943
Oncotarget. 2018 May 4;9(34):23413-23425
pubmed: 29805743
Mol Cancer Ther. 2018 Dec;17(12):2543-2550
pubmed: 30266801
Front Biosci. 2007 Jan 01;12:1814-32
pubmed: 17127423
Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17622-7
pubmed: 15585582
Clin Cancer Res. 2015 Mar 15;21(6):1258-66
pubmed: 25770293
Trends Cancer. 2019 Feb;5(2):111-127
pubmed: 30755304
Neuroscience. 2018 Aug 21;386:315-325
pubmed: 29966721
Nucleic Acids Res. 2014 Feb;42(4):2112-25
pubmed: 24253305
Cancers (Basel). 2019 Jul 26;11(8):
pubmed: 31357444
Int J Mol Sci. 2020 Jul 09;21(14):
pubmed: 32659938
Acta Pharmacol Sin. 2017 May;38(5):591-613
pubmed: 28317871
PLoS One. 2012;7(1):e30441
pubmed: 22276201
Oncogene. 2001 Apr 30;20(19):2453-64
pubmed: 11402340
Nat Commun. 2016 Apr 26;7:11452
pubmed: 27116251
Oncogenesis. 2014 Jun 30;3:e108
pubmed: 24979279
Lancet Oncol. 2013 Jul;14(8):733-40
pubmed: 23735514
Mol Endocrinol. 2013 Apr;27(4):606-18
pubmed: 23393127
Cancer Cell. 2013 Nov 11;24(5):660-72
pubmed: 24183680
BMC Med Genomics. 2019 Jul 11;12(Suppl 5):101
pubmed: 31296229
Reproduction. 2004 Dec;128(6):775-82
pubmed: 15579595
Oncotarget. 2017 May 23;8(34):56868-56879
pubmed: 28915638
J Biol Rhythms. 2018 Oct;33(5):497-514
pubmed: 30175684
Int J Dev Neurosci. 2014 Nov;38:17-22
pubmed: 25068645
Nat Cell Biol. 2015 Mar;17(3):311-21
pubmed: 25686251
EXCLI J. 2014 Aug 18;13:843-55
pubmed: 26417307
Mol Carcinog. 2016 Nov;55(11):1542-1552
pubmed: 26331446
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):986-91
pubmed: 12552083
Int J Mol Sci. 2016 Jul 15;17(7):
pubmed: 27428965
Cancer Res. 2009 Mar 15;69(6):2471-8
pubmed: 19258499
Front Pharmacol. 2018 Jul 20;9:792
pubmed: 30079022
Exp Cell Res. 2017 Oct 15;359(2):405-414
pubmed: 28823831
Trends Neurosci. 2017 Dec;40(12):720-733
pubmed: 29097017
J Cardiovasc Pharmacol. 2018 Nov;72(5):222-230
pubmed: 30403388
J Clin Oncol. 2014 Jul 1;32(19):2039-49
pubmed: 24868024
Adv Exp Med Biol. 2017;1015:19-39
pubmed: 29080019
Pulm Pharmacol Ther. 2017 Aug;45:114-120
pubmed: 28506662
EMBO Rep. 2019 Sep;20(9):e45907
pubmed: 31359606
Biochem J. 2014 Mar 15;458(3):469-79
pubmed: 24438093
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Mol Neurosci. 2015 Apr;55(4):821-9
pubmed: 25316150
Acta Pharmacol Sin. 2017 May;38(5):614-622
pubmed: 28344323
J Biomed Nanotechnol. 2019 Mar 1;15(3):571-580
pubmed: 31165701
Expert Opin Ther Targets. 2015 Jul;19(7):985-95
pubmed: 26036429
Haematologica. 2007 Oct;92(10):1435-7
pubmed: 18024382
Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15805-10
pubmed: 23019365
J Neurochem. 2017 Jun;141(6):808-818
pubmed: 28295333
J Med Chem. 2015 Jun 25;58(12):5075-87
pubmed: 26023867
Int J Mol Sci. 2019 Jan 28;20(3):
pubmed: 30695994
Leukemia. 2015 Jun;29(6):1379-89
pubmed: 25541153
Sci Rep. 2016 Oct 03;6:34513
pubmed: 27694829
Sci Adv. 2020 Feb 19;6(8):eaaw9960
pubmed: 32128390
J Biol Chem. 2000 Nov 10;275(45):35242-7
pubmed: 10952992
Anal Cell Pathol (Amst). 2019 Feb 10;2019:1575031
pubmed: 30881868
Theranostics. 2020 Jan 1;10(1):340-352
pubmed: 31903124
J Dermatol Sci. 2016 Nov;84(2):160-168
pubmed: 27567978
Crit Rev Oncog. 2011;16(1-2):37-46
pubmed: 22150306
Gastric Cancer. 2016 Jan;19(1):74-84
pubmed: 25740226
PLoS One. 2010 Aug 27;5(8):e12452
pubmed: 20805990
Neuro Oncol. 2018 Sep 3;20(10):1344-1355
pubmed: 29718345
Theranostics. 2020 Mar 4;10(9):4017-4029
pubmed: 32226536
Cell Signal. 2008 Mar;20(3):460-6
pubmed: 17993258
Mol Cancer Res. 2015 Aug;13(8):1248-62
pubmed: 25934695
J Struct Biol. 2010 May;170(2):216-25
pubmed: 20176111
Clin Cancer Res. 2009 Apr 15;15(8):2583-7
pubmed: 19351775
Front Neurosci. 2019 Jan 07;12:990
pubmed: 30666179
Cancer Treat Rev. 2017 Jan;52:12-21
pubmed: 27883925
Tumour Biol. 2016 Oct;37(10):13077-13090
pubmed: 27596143